Aclaris Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	15.74	18.72	31.25	29.5	6.64	6.48
Other Revenue	-	-	-	0.26	0.12	0.01
Revenue	15.74	18.72	31.25	29.75	6.76	6.48
Revenue Growth (YoY)	-41.87%	-40.09%	5.03%	340.05%	4.30%	53.35%
Cost of Revenue	59.14	49.04	114.25	89.77	48.53	34.47
Gross Profit	-43.4	-30.32	-83	-60.02	-41.77	-27.99
Selling, General & Admin	21.35	22.2	31.51	25.13	23.62	20.53
Research & Development	1.06	-	-	-	-	-
Operating Expenses	22.41	22.2	31.51	25.13	23.62	20.53
Operating Income	-65.81	-52.53	-114.51	-85.15	-65.38	-48.52
Interest & Investment Income	8.11	7.95	8.51	-	-	-
Other Non Operating Income (Expenses)	3.53	1.91	-	2.95	-1.14	-0.42
EBT Excluding Unusual Items	-54.18	-42.66	-106	-82.21	-66.53	-48.94
Merger & Restructuring Charges	-	-	-3.12	-	-	-
Other Unusual Items	-0.6	-2.5	26.9	-4.7	-24.34	-2.39
Pretax Income	-141.68	-132.07	-88.85	-86.91	-90.87	-51.34
Income Tax Expense	-	-	-0.37	-	-	-0.18
Earnings From Continuing Operations	-141.68	-132.07	-88.48	-86.91	-90.87	-51.15
Earnings From Discontinued Operations	-	-	-	-	-	0.14
Net Income	-141.68	-132.07	-88.48	-86.91	-90.87	-51.02
Net Income to Common	-141.68	-132.07	-88.48	-86.91	-90.87	-51.02
Shares Outstanding (Basic)	116	77	70	65	57	43
Shares Outstanding (Diluted)	116	77	70	65	57	43
Shares Change (YoY)	62.68%	10.73%	7.05%	14.95%	33.36%	2.94%
EPS (Basic)	-1.22	-1.71	-1.27	-1.33	-1.60	-1.20
EPS (Diluted)	-1.22	-1.71	-1.27	-1.33	-1.60	-1.20
Free Cash Flow	-43.01	-20.2	-79.63	-68.17	-52.44	-39.09
Free Cash Flow Per Share	-0.37	-0.26	-1.14	-1.04	-0.92	-0.92
Gross Margin	-275.68%	-161.99%	-265.60%	-201.74%	-	-
Operating Margin	-418.06%	-280.59%	-366.44%	-286.21%	-967.08%	-748.52%
Profit Margin	-900.01%	-705.48%	-283.15%	-292.11%	-1343.96%	-787.03%
Free Cash Flow Margin	-273.20%	-107.89%	-254.84%	-229.13%	-775.65%	-602.99%
EBITDA	-65.74	-52.22	-114.45	-	-65.06	-48.2
EBITDA Margin	-	-278.95%	-	-	-	-
D&A For EBITDA	0.07	0.31	0.06	-	0.32	0.32
EBIT	-65.81	-52.53	-114.51	-85.15	-65.38	-48.52
EBIT Margin	-	-280.59%	-	-286.21%	-	-
Revenue as Reported	15.74	18.72	31.25	29.75	6.76	6.48

Source: S&P Global Market Intelligence. Standard template. Financial Sources.